Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShares OutstandingWages, Salaries and Other
Ratios

UroGen Pharma (URGN) Accumulated Depreciation & Amortization: 2016-2025

Historic Accumulated Depreciation & Amortization for UroGen Pharma (URGN) over the last 9 years, with Sep 2025 value amounting to $4.5 million.

  • UroGen Pharma's Accumulated Depreciation & Amortization rose 7.12% to $4.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.6 million, marking a year-over-year increase of 7.29%. This contributed to the annual value of $4.3 million for FY2024, which is 8.32% up from last year.
  • Latest data reveals that UroGen Pharma reported Accumulated Depreciation & Amortization of $4.5 million as of Q3 2025, which was up 1.80% from $4.4 million recorded in Q2 2025.
  • In the past 5 years, UroGen Pharma's Accumulated Depreciation & Amortization registered a high of $4.5 million during Q3 2025, and its lowest value of $200,000 during Q1 2021.
  • Over the past 3 years, UroGen Pharma's median Accumulated Depreciation & Amortization value was $4.1 million (recorded in 2024), while the average stood at $4.1 million.
  • Data for UroGen Pharma's Accumulated Depreciation & Amortization shows a peak YoY skyrocketed of 2,126.00% (in 2021) over the last 5 years.
  • Over the past 5 years, UroGen Pharma's Accumulated Depreciation & Amortization (Quarterly) stood at $2.2 million in 2021, then soared by 41.51% to $3.1 million in 2022, then rose by 25.46% to $4.0 million in 2023, then grew by 8.32% to $4.3 million in 2024, then rose by 7.12% to $4.5 million in 2025.
  • Its Accumulated Depreciation & Amortization stands at $4.5 million for Q3 2025, versus $4.4 million for Q2 2025 and $4.4 million for Q1 2025.